InnoBM Pharmaceuticals Co., Ltd. (InnoBM), a pioneering biotechnology firm, has announced the successful completion of a Series A funding round that surpassed RMB 100 million this fiscal year. The investment was led by a consortium of esteemed venture capital firms, including Yuanbio Ventures Capital, LH Ventures, DHVC, Leader Ventures.

With this capital injection, InnoBM is poised to accelerate the development of its innovative product pipeline and further refine its state-of-the-art technological platform. Our lead candidate, BM201, a promising therapy for advanced solid tumors in combination with radiotherapy, is entering a pivotal stage with the imminent enrollment of the first patient. This is a testament to the strong support and collaboration from leading clinical institutions and researchers.

InnoBM remains committed to pushing the boundaries of biopharmaceutical innovations, leveraging our expertise in delivery and controlled-release technologies, as well as immune microenvironment modulation. Our interdisciplinary approach, rooted in biomaterial technology, is designed to bridge the gap between groundbreaking research and real-world applications, ultimately addressing the unmet clinical needs of patients worldwide.

Founder and CEO, Professor Liu Zhuang, expressed his heartfelt gratitude to all investors for their trust and support. "This funding round is not only a validation of our innovative capabilities but also a catalyst for our continued growth and impact. We are excited to embark on this new chapter, driven by our mission to deliver transformative therapies that make a difference in patients' lives."

As we move forward, InnoBM will continue to innovate and collaborate, striving to be at the forefront of biopharmaceutical advancements and making a lasting impact on global healthcare.